Enanta Pharmaceuticals Inc (ENTA): Nathaniel S. Gardiner , Sr. VP & General Counsel of Enanta Pharmaceuticals Inc purchased 500 shares on May 11, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $24.44 per share for a total value of $12,222.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 17, 2016, Terry Vance (director) purchased 2,000 shares at $27.04 per share price.On Nov 25, 2015, Paul J Mellett (Treasurer and CFO) sold 6,000 shares at $31.23 per share price.Also, On Aug 11, 2015, Yat Sun Or (Chief Scientific Officer) sold 3,750 shares at $42.96 per share price.On Mar 10, 2015, Jay R. Luly (President and CEO) sold 15,000 shares at $34.03 per share price.
Shares of Enanta Pharmaceuticals Inc (ENTA) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.93 points or -3.65% at $24.52 with 7,43,805 shares getting traded. Post opening the session at $23, the shares hit an intraday low of $23 and an intraday high of $25.33 and the price vacillated in this range throughout the day. The company has a market cap of $464 M and the number of outstanding shares has been calculated to be 1,89,25,311 shares. The 52-week high of Enanta Pharmaceuticals Inc is $51.89 and the 52-week low is $16.75.
Company has been under the radar of several Street Analysts.Enanta Pharmaceuticals Inc is Downgraded by JMP Securities to Mkt Perform. Earlier the firm had a rating of Mkt Outperform on the company shares. The Rating was issued on Apr 28, 2016.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.